nach oben

Erschienen in:

16.09.2019 | Original Article

Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy

verfasst von: Stefania Crucitta, Giuliana Restante, Marzia Del Re, Ilaria Bertolini, Eleonora Bona, Eleonora Rofi, Lorenzo Fontanelli, Giulia Gianfilippo, Stefano Fogli, Irene Stasi, Matteo Ghilli, Andrea Fontana, Romano Danesi

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the association between single nucleotide polymorphisms (SNPs) in endothelial nitric oxide synthase (eNOS) and interleukin-8 (IL-8) genes and risk of developing bevacizumab-related adverse events in metastatic breast cancer (mBC) patients.

Patients and methods

mBC patients candidate to receive bevacizumab-based chemotherapy were enrolled in this pharmacogenetic study. eNOS c.-813C>T and c.894G>T, and IL-8 c.-251A>T were analyzed by real time PCR on genomic DNA extracted from peripheral blood. Univariate analysis was performed to test the association between each SNP and treatment-related toxicities.

Results

Seventy-six mBC patients were enrolled in the present study. Patients carrying the homozygous variant eNOS c.-813TT genotype showed a statistically significant occurrence of any grade proteinuria when compared to CT or CC genotypes (p = 0.004). No significant association of proteinuria with IL-8 SNP or hypertension with selected eNOS and IL-8 SNPs was found.

Conclusions

These findings suggest an association between the eNOS c.-813C>T polymorphism and the development of proteinuria in mBC patients receiving a bevacizumab-based chemotherapy.

Rajabi M, Mousa SA (2017) The role of angiogenesis in cancer treatment. Biomedicines 5:2. https://doi.org/10.3390/biomedicines5020034 CrossRef

Giuliano S, Pages G (2013) Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 95(6):1110–1119. https://doi.org/10.1016/j.biochi.2013.03.002 CrossRefPubMed

Redondo A, Ramos Vazquez M, Manso L, Gil Gil MJ, Garau Llinas I, Garcia-Garre E, Rodriguez CA, Chacon JI, Lopez-Vivanco G (2018) Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. Onco Targets Ther 11:5845–5852. https://doi.org/10.2147/OTT.S170303 CrossRefPubMedPubMedCentral

Raouf S, Bertelli G, Ograbek A, Field P, Tran I (2019) Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. Future Oncol 15(5):543–561. https://doi.org/10.2217/fon-2018-0480 CrossRefPubMed

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676. https://doi.org/10.1056/NEJMoa072113 CrossRefPubMed

Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23(5):460–468. https://doi.org/10.1038/ajh.2010.25 CrossRefPubMed

Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21(8):1381–1389. https://doi.org/10.1681/ASN.2010020167 CrossRefPubMedPubMedCentral

Schmidinger M (2013) Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl 11(2):172–191. https://doi.org/10.1016/j.ejcsup.2013.07.016 CrossRefPubMedPubMedCentral

Hayman SR, Leung N, Grande JP, Garovic VD (2012) VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 14(4):285–294. https://doi.org/10.1007/s11912-012-0242-z CrossRefPubMedPubMedCentral

10.

Bachmann S, Bosse HM, Mundel P (1995) Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol 268(5 Pt 2):F885–F898. https://doi.org/10.1152/ajprenal.1995.268.5.F885 CrossRefPubMed

11.

Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H (2003) Protective role of endothelial nitric oxide synthase. J Pathol 199(1):8–17. https://doi.org/10.1002/path.1250 CrossRefPubMed

12.

Li M, Kroetz DL (2018) Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther 182:152–160. https://doi.org/10.1016/j.pharmthera.2017.08.012 CrossRefPubMed

13.

Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M (2007) Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 18(12):5014–5023. https://doi.org/10.1091/mbc.e07-01-0004 CrossRefPubMedPubMedCentral

14.

Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE (2002) Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 12(5):407–413CrossRef

15.

Doshi AA, Ziolo MT, Wang H, Burke E, Lesinski A, Binkley P (2010) A promoter polymorphism of the endothelial nitric oxide synthase gene is associated with reduced mRNA and protein expression in failing human myocardium. J Card Fail 16(4):314–319. https://doi.org/10.1016/j.cardfail.2009.12.013 CrossRefPubMedPubMedCentral

16.

Metzger IF, Sertorio JT, Tanus-Santos JE (2007) Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 43(6):987–992. https://doi.org/10.1016/j.freeradbiomed.2007.06.012 CrossRefPubMed

17.

Godfrey V, Chan SL, Cassidy A, Butler R, Choy A, Fardon T, Struthers A, Lang C (2007) The functional consequence of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers. Cardiovasc Drug Rev 25(3):280–288. https://doi.org/10.1111/j.1527-3466.2007.00017.x CrossRefPubMed

18.

Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P (2002) The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 20(10):2023–2027CrossRef

19.

Di Salvatore M, Lo Giudice L, Rossi E, Santonocito C, Nazzicone G, Rodriquenz MG, Cappuccio S, Inno A, Fuso P, Orlandi A, Strippoli A, Capoluongo E, Astone A, Cassano A, Barone C (2016) Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. Clin Transl Oncol 18(1):40–46. https://doi.org/10.1007/s12094-015-1334-7 CrossRefPubMed

20.

Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C (2017) IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. Oncotarget 8(10):16887–16898. https://doi.org/10.18632/oncotarget.14810 CrossRefPubMedPubMedCentral

21.

Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14(22):7554–7563. https://doi.org/10.1158/1078-0432.CCR-08-0351 CrossRefPubMedPubMedCentral

22.

Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D (2015) eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. J Transl Med 13:258. https://doi.org/10.1186/s12967-015-0619-5 CrossRefPubMedPubMedCentral

23.

Allegrini G, Coltelli L, Orlandi P, Fontana A, Camerini A, Ferro A, Cazzaniga M, Casadei V, Lucchesi S, Bona E, Di Lieto M, Pazzagli I, Villa F, Amoroso D, Scalese M, Arrighi G, Molinaro S, Fioravanti A, Finale C, Triolo R, Di Desidero T, Donati S, Marcucci L, Goletti O, Del Re M, Salvadori B, Ferrarini I, Danesi R, Falcone A, Bocci G (2014) Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. Pharmacogenomics 15(16):1985–1999. https://doi.org/10.2217/pgs.14.140 CrossRefPubMed

24.

Oliveira-Paula GH, Lacchini R, Tanus-Santos JE (2017) Clinical and pharmacogenetic impact of endothelial nitric oxide synthase polymorphisms on cardiovascular diseases. Nitric Oxide 63:39–51. https://doi.org/10.1016/j.niox.2016.08.004 CrossRefPubMed

25.

Lafayette RA, McCall B, Li N, Chu L, Werner P, Das A, Glassock R (2014) Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials. Am J Nephrol 40(1):75–83. https://doi.org/10.1159/000365156 CrossRefPubMed

26.

Wang XL, Wang J (2000) Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab 70(4):241–251. https://doi.org/10.1006/mgme.2000.3033 CrossRefPubMed

27.

Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J (2000) Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 97(6):2832–2835. https://doi.org/10.1073/pnas.97.6.2832 CrossRefPubMed

28.

Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T, Igari J (1998) Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 245(1):190–193. https://doi.org/10.1006/bbrc.1998.8267 CrossRefPubMed

29.

Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, van Herpen CM, Haanen JB, Mathijssen RH, Boven E (2012) Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 92(4):503–510. https://doi.org/10.1038/clpt.2012.136 CrossRefPubMed

30.

Garsen M, Rops AL, Li J, van Beneden K, van den Branden C, Berden JH, Rabelink TJ, van der Vlag J (2016) Endothelial nitric oxide synthase prevents heparanase induction and the development of proteinuria. PLoS One 11(8):e0160894. https://doi.org/10.1371/journal.pone.0160894 CrossRefPubMedPubMedCentral

31.

Niu W, Qi Y (2011) An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension. PLoS One 6(9):e24266. https://doi.org/10.1371/journal.pone.0024266 CrossRefPubMedPubMedCentral

32.

Garsen M, Lenoir O, Rops AL, Dijkman HB, Willemsen B, van Kuppevelt TH, Rabelink TJ, Berden JH, Tharaux PL, van der Vlag J (2016) Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx. J Am Soc Nephrol 27(12):3545–3551. https://doi.org/10.1681/ASN.2015091070 CrossRefPubMedPubMedCentral

33.

Momeni A, Chaleshtori MH, Saadatmand S, Kheiri S (2016) Correlation of endothelial nitric oxide synthase gene polymorphism (GG, TT and GT genotype) with proteinuria and retinopathy in Type 2 diabetic patients. J Clin Diagn Res 10(2):OC32–OC35. https://doi.org/10.7860/jcdr/2016/14975.7291 CrossRefPubMedPubMedCentral

34.

Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL (2016) eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget 7(19):27988–27999. https://doi.org/10.18632/oncotarget.8569 CrossRefPubMed

35.

Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C (2012) The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10(1):4–18CrossRef

36.

Kowalski TW, Fraga LR, Tovo-Rodrigues L, Sanseverino MT, Hutz MH, Schuler-Faccini L, Vianna FS (2016) New findings in eNOS gene and thalidomide embryopathy suggest pre-transcriptional effect variants as susceptibility factors. Sci Rep 6:23404. https://doi.org/10.1038/srep23404 CrossRefPubMedPubMedCentral

37.

Yoshimura M, Nakayama M, Shimasaki Y, Ogawa H, Kugiyama K, Nakamura S, Ito T, Mizuno Y, Harada E, Yasue H, Miyamoto Y, Saito Y, Nakao K (2000) A T-786–>C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene and coronary arterial vasomotility. Am J Cardiol 85(6):710–714CrossRef

38.

Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, Wada J, Makino H (1998) Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 41(12):1426–1434. https://doi.org/10.1007/s001250051088 CrossRefPubMed

39.

Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB (2000) Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 11(1):71–79PubMed

40.

Shoukry A, Shalaby SM, Abdelazim S, Abdelazim M, Ramadan A, Ismail MI, Fouad M (2012) Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus. Genet Test Mol Biomark 16(6):574–579. https://doi.org/10.1089/gtmb.2011.0218 CrossRef

41.

Ezzidi I, Mtiraoui N, Mohamed MB, Mahjoub T, Kacem M, Almawi WY (2008) Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and −786T>C gene variants with diabetic nephropathy. J Diabetes Complicat 22(5):331–338. https://doi.org/10.1016/j.jdiacomp.2007.11.011 CrossRefPubMed

42.

Sun L, Mao D, Cai Y, Tan W, Hao Y, Li L, Liu W (2016) Association between higher expression of interleukin-8 (IL-8) and haplotype −353A/−251A/+678T of IL-8 gene with preeclampsia: a case–control study. Medicine (Baltimore) 95(52):e5537. https://doi.org/10.1097/MD.0000000000005537 CrossRef

Titel: Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy
verfasst von: Stefania Crucitta
Giuliana Restante
Marzia Del Re
Ilaria Bertolini
Eleonora Bona
Eleonora Rofi
Lorenzo Fontanelli
Giulia Gianfilippo
Stefano Fogli
Irene Stasi
Matteo Ghilli
Andrea Fontana
Romano Danesi
Publikationsdatum: 16.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03933-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy

Abstract

Purpose

Patients and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Patients and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry

Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial

Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study

JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie